Evaluation of Anti-Secretory and Anti-Ulcerogenic Activities of Avipattikar Churna on The Peptic Ulcers in Experimental Rats

ABSTRACT

Background: Avipattikar churna, a poly-herbal formulation, is one of the popular ayurvedic formulations which is used for peptic ulcer diseases but the scientific documentation with regards to its effect for the indication is lacking.

Aims: This study was carried out to evaluate the anti-secretory and the anti-ulcerogenic activities of the churna and to compare its activity with that of ranitidine in a pyloric ligated model of rats.

Material and methods: Four groups of rats with 6 animals in each served as the ulcer controls, churna low dose (500 mg/kg), churna high dose (750 mg/kg) and ranitidine (25 mg/kg). The control group rats received only vehicle (2% (v/v) gum acacia), while the rats of the other groups received the respective dose of the churna or ranitidine which was suspended in the vehicle. The treatments were given twice a day, orally, for two days. After 1 hour of the last dose, pyloric ligations were performed and the rats were sacrificed for evaluation after four hours of the ligations. The gastric contents were collected and its volumes, pH and acidity were measured. The numbers of ulcers and their lengths were measured which were used to calculate the gastric irritancy index and the curative ratio. The histological examinations of the gastric tissues were also performed.

Results: The churna, in both doses, significantly decreased the volumes of the gastric contents, the ulcer score, the length of the ulcer, the gastric irritancy index and pH increased as compared to those in the control group. The effects of the churna were comparable to that of ranitidine. The histopathological evaluation of the gastric tissue also supported the results.

Conclusion: Avipattikar churna has anti-secretory and anti-ulcerogenic effects which are comparable to those of ranitidine in peptic ulcer diseases.

Key Words: Avipattikar churna, Gastric acid, Peptic ulcer, Pyloric ligation, Ranitidine, Rats

INTRODUCTION

Peptic ulcer refers to an ulcer in the lower oesophagus, stomach or the intestinal mucosa [1]. The ulceration results when the aggressive factors (acid, pepsin, bile or H. pylori) overwhelm the defensive factors of the gastrointestinal mucosa (mucus and bicarbonate secretions, prostaglandins and nitric oxide) [2]. It affects 8-10% of the global population [3]. Although, the epidemiological studies show the high prevalence of the disease in the developing countries [1], twenty five million (approx.) Americans suffer from peptic ulcer diseases [4].

Various drugs like Proton Pump Inhibitors, H₂ receptor antagonists, anti H. pylori etc. which have fast therapeutic actions and proven efficacies are used in the treatment of peptic ulcers in the allopathic system [1, 2]. But due to the drawbacks of the allopathic medicines (mostly the safety issue) and other reasons, people are interested in herbal formulations [5].

Avipattikar churna, a polyherbal Ayurvedic formulation which is popular for the treatment of peptic ulcer, is composed of fourteen different ingredients, which include: Shunthi (Zingiber officinale), Maricha (Piper nigrum), Pippali (Piper longum), Haritaki (Terminalia chebula), Vibhitaka (Terminalia bellerica), Aamalaki (Emblica officinalis), Musta (Cyperus rotundus), salt (Vida Lavana), Vidanga (Emblica ribes), Ela (Amomum subulatum), Patra (Cinnamomum tamala), Lavanga (Syzygium aromaticum), Trivrit (Operculina terpethum) and Sharkara (Sugar candy). All the components are present in 11, 44 and 66 parts respectively. Therapeutic dose of the churna for peptic ulcer disease is 3-6 grams with water, before or after meals [6].

The ingredients of Avipattikar churna exhibit antulcer properties. Haritaki, Maricha and Pippali exert cytotoxic effects on the gastric mucosa [7-9]. Shunthi decreases the gastric secretion, increases the mucosal resistance and potentiates the defensive factors of the gastric mucosa [10]. Lavanga helps in maintaining the basal gastric mucosal blood flow and it increases the mucus secretion [11].

Although Avipattikar churna is popularly used in peptic ulcer diseases [6], there is a lack of scientific documents to support its use in peptic ulcer. Hence, this study was taken up to evaluate the anti-secretory and anti-ulcerogenic effects of Avipattikar churna and to compare its efficacy with that of Ranitidine.

MATERIALS AND METHODS

A freshly prepared sample of Avipattikar churna (batch no. SAC-
184) was obtained from Singhadurbar Vaidyakhana Vikas Samiti, Anamnagar, Kathmandu, Nepal. The reference drug, ranitidine (batch no. 67-68/503/01) was obtained from National Health Care P. Ltd., Chhatapipara, Birgunj.

**Experiment site:** This study was conducted in September 2011 at the pharmacology laboratory of the School of Health and Allied Sciences, Pokhara University, Nepal, after obtaining clearance (Ref. No. 101/2068-069) from the Research and Ethical committee of the university.

**Animals:** Sprague Dawley male rats (200-350g) were housed individually in polypropylene cages under standard husbandry conditions. They had been given the standard diet [12], protein-20%, carbohydrate-60%, fat-5% and fibre-5% and water ad. libitum.

Twenty four rats were divided into four groups, with six animals in each group. They were fasted with free access of water for a period of 24 hours, to ensure a complete gastric emptying and a steady state gastric secretion. The group I rats served as the ulcer controls and they received vehicle [2 % (v/v) gum acacia], group II served as the churna low dose (CLD) group and received the churna (500 mg/kg), group III served as the churna high dose (CHD) group and received the churna (750 mg/kg) and group IV served as the ranitidine reference control group and received ranitidine (25 mg/kg).

**Gastric ulcer induction in the rats:** Shay’s pyloric technique (1945) was used to induce gastric ulcers in the rats [13, 14]. The churna and ranitidine were suspended in the vehicle (2% (v/v) gum acacia) and they were administered via oral route with the help of feeding tube. The drugs were administered twice a day, with a dosing interval of 12 hours, for two days. After 1 hour of the last dose, pyloric ligations were performed in all the rats under general anaesthesia (ether). The pyloric ligated animals were housed separately in their groups. Food and water were withheld for a duration of 4 hours. Finally, all the rats were sacrificed by using an overdose of the ether anaesthetic. The stomach of each rat was removed separately after tying the lower oesophageal end. The stomach was incised along the greater curvature and the gastric contents were centrifuged at 1500rpm for 10 minutes. The total volume of the supernatant liquid was measured and it was expressed in terms of ml/100g of the body weight of the rats. The pH was determined by using a digital pH meter. For the estimation of the total acidity, the diluted supernatant was titrated with 0.01N NaOH by using the Phenolphthalein reagent as an indicator [14].

After rinsing the stomach with normal saline (pH 7.0), it was stretched on a frog-board and with the help of a magnifying glass, the degree of ulceration was graded from zero to five. The graded number was expressed as the ulcer score [13-15]. The length of each ulcer in an individual stomach was measured with the help of a millimetre (mm) scale and it was summed up, which was denoted as the Gastric irritancy size (GIS). The total number of ulcers per stomach gave the Ulcer Number (UN). The Gastric Irritancy Index (GII) was then calculated by multiplying the GIS with the UN [16]. The difference in the average length of the ulcers in the control and the treated groups was also calculated. The difference which was divided by the average length of the ulcer in the control group and multiplied by hundred was expressed as the curative ratio [17].

**Histopathological evaluation:** The tissue specimens which were preserved in formalin were accessioned separately and processed through the steps of dehydration (with ethanol), clearing and embedding (with paraffin). Thus formed paraffin blocks were cut by using a rotary microtome. The sections were then fixed onto glass slides, stained with eosin and evaluated.

**STATISTICAL ANALYSIS**

SPSS (Statistical Package for the Social Sciences), version 17 was used to analyze the data. The results were presented as MEAN ± SEM. The data were processed for obtaining a ‘p’ value by one way ANOVA, followed by the Dunnett test. A ‘p’ value of less than 0.01 was considered as statistically significant.

**RESULTS**

**Table/Fig-1** shows the various parameters in the different groups. The difference in each group was compared individually with the results of the control group and the statistically significant (p<0.01) results were marked by (*). Similarly, the difference in each group was also compared individually with the results of the ranitidine treated group and the statistically significant (p<0.01) results were marked by the addition sign (+).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Groups</th>
<th>Ulcer Control (mean ± SEM)</th>
<th>Churna (500mg/kg) (mean ± SEM)</th>
<th>Churna (750mg/kg) (mean ± SEM)</th>
<th>Ranitidine (25mg/kg) (mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume of gastric content (ml/100g)</td>
<td>4.6150±0.118*</td>
<td>1.338±0.177*</td>
<td>1.675±0.270*</td>
<td>1.980±0.518*</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>3.3017±0.145*</td>
<td>4.705±0.235*</td>
<td>4.263±0.141*</td>
<td>4.181±0.302*</td>
<td></td>
</tr>
<tr>
<td>Acidity</td>
<td>153.216±1.976*</td>
<td>91.016±1.163*</td>
<td>111.25±2.042</td>
<td>78.366±6.095*</td>
<td></td>
</tr>
<tr>
<td>ulcer score</td>
<td>2.000±0.632*</td>
<td>0.750±0.483*</td>
<td>0.750±0.316*</td>
<td>0.750±0.795*</td>
<td></td>
</tr>
<tr>
<td>length of ulcer (mm)</td>
<td>12.733±1.063*</td>
<td>0.628±0.563*</td>
<td>0.986±0.548*</td>
<td>0.5233±0.456*</td>
<td></td>
</tr>
<tr>
<td>No. of ulcer</td>
<td>4.333±1.123*</td>
<td>2.666±0.500</td>
<td>2.166±0.480</td>
<td>2.166±0.511</td>
<td></td>
</tr>
<tr>
<td>GII</td>
<td>60.800±5.381*</td>
<td>1.510±0.661*</td>
<td>1.910±0.503*</td>
<td>1.200±0.630*</td>
<td></td>
</tr>
<tr>
<td>Curative ratio</td>
<td>95.065</td>
<td>92.251</td>
<td>95.890</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Evaluation of the parameters in comparison to those of the control group**

The mean gastric contents of the ulcer control group was 4.615ml (maximum) and that of the CLD group was 1.338 (minimum). The mean volume of the gastric contents, acidity, the length of the ulcer and GII were significantly low in all the treated groups as compared individually with those in the control group. The decrease in the CLD group was significant as compared to that in the control group for all the parameters. The results among the churna treated groups (CLD and CHD) were not statistically significant at a p value of <0.01.

**Evaluation of the parameters in comparison to those of the ranitidine treated group**

When the results of the churna treated groups were compared separately with the results of the ranitidine treated group for vari-
ous parameters, the differences which were observed were found
to be statistically not significant.

**DISCUSSION**

There are various methods for the production of peptic ulcers in
animals and pyloric ligation is one of the most commonly used
methods [13, 14]. Pyloric ligation causes accumulation of the
gastric juice and hindrance of the gastric blood circulation, which
lead to damage of the upper gastrointestinal tract and the forma-
tion of ulcers [16, 18]. In our study, pyloric ligation significantly
elevated the gastric acid secretion, acidity and the ulcer score
and it decreased the pH of the gastric contents. In a similar type
of study [19], the pyloric ligation was found to decrease the pH
to 3.36 in the control rats. Similarly, it was reported to decrease
the pH to 3.21 in another study [20]. In our study, the gastric pH
decreased up to 3.30, which probably indicated that the ligation
was effective in our study.

Ranitidine, a commonly used H₂ blocker, inhibits the acid produc-
tion by reversibly blocking the H₂ receptors on the basolateral
membrane of the parietal cells [1, 2]. The volume of the gastric
juice in the ranitidine, CLD and the CHD treated groups were
1.9800 ± 0.518, 1.3383 ± 0.177 and 1.675 ± 0.270 ml respec-
tively, which was significantly (p<0.01) less, as compared to that
in the control group (4.6150 ± 0.118 ml). The results were com-
parable with those of a similar type of Indian study [19], where
the mean volume of the gastric secretion in the ranitidine treated,
Avipattikar churna extract (500mg/kg) treated and the control
groups were 1.916, 2.466 and 4.25 ml respectively. The churna
showed a good antisecretory activity in our study, which could
have been due to the variations in the quality of the churna or the
use of the raw drug in our study, unlike in the other study [19]. In
Ayurveda, a raw drug (without extraction) is said to contain vari-

---

**Histological examination of the gastric tissue:** [Table/Fig-2]
shows the normal architecture of the gastric tissues of the rats,
with a distinct serosal layer, muscularis and the mucosal and the
submucosal layers of the stomach. The photomicrograph of a
stomach from the ulcer control group [Table/Fig-3] showed dead
neutrophils with pus formation and fibrinopurulent exudates. The
histological examination of the gastric tissues of the CLD and
the CHD treated groups showed healing of the ulcers, with few
inflammatory cells (eosinophils, lymphocytes and plasma cells)
at the mucosal layer [Table/Fig-4 and 5] as compared to those
of the ulcer control group. The architecture of the gastric tissue
was less distorted (almost normal) in the ranitidine treated group
[Table/Fig-6].
ous components which work synergistically and give good effects with low side effects.

There were significant decreases in the acidity in the ranitidine and the CLD treated groups as compared to those in the ulcer control group. However, the decrease in the acidity in the CHD group was insignificant as compared to that in the control group. The pyloric ligation causes the accumulation of acid, which irritates the stomach wall and the stress which is caused by the ligation, further increases the irritation [18]. In all the treated groups, there were statistically significant decreases in the GII as compared to those in the ulcer control group. This indicated that the churna and ranitidine, both help in the prevention of GII. Furthermore, the differences in the GII among the treated groups were statistically insignificant, which signified that the churna was as effective as ranitidine in controlling the irritation. The differences in the curative ratios between the CLD (95.065), CHD (92.251) and the ranitidine (95.890) groups were also statistically not significant.

Ranitidine reduced the gastric acid secretion, it reduced the ulcer score and it increased the pH, thus showing an anti-ulcerogenic effect. The test drug, Avipattikar churna (especially at 500mg/kg dose) was found to be equally efficacious with the reference drug, ranitidine (25mg/kg). There were no significant differences among the CLD, CHD and the ranitidine treated groups with respect to the compared parameters. Although the CHD group received a higher dose (750mg/kg) than the CLD group (500mg/kg), the effect on the various parameters was almost the same (or some time less). At a 750mg/kg dose, the quantity which was administered became very high, to the extent that it could have led to indigestion and adversely affect the anti-secretory and the anti-ulcerogenic activities of the churna.

The histological evaluation of the gastric tissues of the rats from various groups also supported the results. The churna prevented the damage of the gastric tissues which could be caused by the excessive acid secretion and thus, it provided a less distorted gastric mucosal architecture which was comparable to that of the ranitidine treated rat gastric tissue. The inflammatory cells at the mucosal layer of the gastric tissue of the churna treated group were lesser than in the ulcer control group, which added evidence of the effective healing property of the Avipattikar churna. Similar types of histopathological results were also obtained in the study which was conducted by Aswatha RHN et al., [16].

LIMITATIONS

This study was limited to the ulcers which were caused by the pyloric ligation method only and so our results may not be applicable to the studies where the ulcers are produced by other methods. The quality of the churna which was used in this study was not assessed. Pharmacognostic tests e.g. the ash value, the saponification value, acid-insoluble ash, the water-soluble ash values, the moisture content, etc were not performed before the study due to time limitations.

CONCLUSION

The test drug, Avipattikar churna, showed anti-secretory and anti-ulcerogenic effects against the gastric ulcers which were induced by a pyloric ligation. The anti-secretory and the anti-ulcerogenic activities of the churna were similar to those of ranitidine. A good therapeutic effect was observed at a 500 mg/kg dose of the churna.

ACKNOWLEDGEMENT

It was our privilege to receive the grant from the Nepal Health Research Council (NHRC), Ramshah Path, Kathmandu, Nepal, to conduct this extensive research. We would like to thank Dr. Duk Bahadur Chhetri, Consultant Pathologist, Western Regional Hospital, Pokhara, for his help in the histopathological studies. We would like to put on record our appreciation to Prof. Dr. Mohan Amatyaa, Resource Officer and Mrs. Nabin Badan Pradhan, Asst. Resource Officer, Natural Product Research Laboratory, Department of Plant Resources, Thapathali, Kathmandu, for providing the animals and for the development of the technique.

REFERENCES

AUTHOR(S):
1. Mr. Sudesh Gyawali
2. Mr. Gulam Muhammad Khan
3. Mr. Shreekrishna Lamichane,
4. Ms. Jaya Gautam
5. Mr. Saurav Ghimire
6. Ms. Rashmi Adhikari
7. Ms. Reshma Lamsal

PARTICULARS OF CONTRIBUTORS:
1. Assistant Professor, Department of Pharmacology, Manipal College of Medical Sciences (MCOMS), Deepheight, Pokhara, Nepal.
2. Associate Professor, Department of Pharmacy, School of Health & Allied Sciences, Pokhara University, Nepal.
3. Student, Department of Pharmacy, School of Health & Allied Sciences, Pokhara University, Nepal.
4. Student, Department of Pharmacy, School of Health & Allied Sciences, Pokhara University, Nepal.
5. Student, Department of Pharmacy, School of Health & Allied Sciences, Pokhara University, Nepal.
6. Student, Department of Pharmacy, School of Health & Allied Sciences, Pokhara University, Nepal.
7. Student, Department of Pharmacy, School of Health & Allied Sciences, Pokhara University, Nepal.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:
Mr. Sudesh Gyawali,
Assistant Professor, Department of Pharmacology, Manipal College of Medical Sciences (MCOMS), P.O. Box: 155, Deepheight, Pokhara, Nepal.
Phone: 00977-9848032051
Fax: 00977-61-440260
E-mail: sudesh34@yahoo.com

FINANCIAL OR OTHER COMPETING INTERESTS:
None.

Date of Submission: Nov 12, 2012
Date of Peer Review: Feb 27, 2013
Date of Acceptance: Apr 07, 2013
Date of Publishing: Jun 01, 2013